不同剂量阿托伐他汀对不稳定型心绞痛患者白介素-6和高敏C-反应蛋白的影响

目的 探讨不同剂量阿托伐他汀对不稳定型心绞痛患者白介素-6(IL-6)和高敏C-反应蛋白(hs-CRP)的影响.方法 94例不稳定型心绞痛患者随机分为3组,对照组给予常规治疗,对照治疗组在常规治疗基础上给予阿托伐他汀10 mg/d,治疗组在常规治疗基础上给予阿托伐他汀20 mg/d,测定治疗前后血脂、IL-6及hs-CRP的变化.结果 对照治疗组及治疗组在治疗后血脂、IL-6及hs-CRP水平较治疗前均有显著下降(P＜0.01),且治疗组较对照治疗组下降更明显(P＜0.01);对照治疗组及治疗组治疗前后血脂下降与IL-6及hs-CRP下降无相关性(P＞0.05).结论 阿托伐他汀可降低不稳定型心绞痛患者的血脂、IL-6及hs-CRP水平,20 mg优于10 mg,其抗炎作用不依赖降脂作用.

Effects of different doses of atorvastatin on interleukin-6 and hypersensitive C-reactive protein in patients with unstable angina pectoris

Objective To investigate the effects of different doses of atorvastatin on interleukin-6 （IL-6） and hypersensitive C-reactive protein （hs-CRP）in patients with unstable angina pectoris （UAP）. Methods 94 patients with UAP were randomly divided into three groups： the patients in control group were given routine therapy, the patients in control treatment group, on the basis of control group,were givenatorvastatin 10mg, and the patients in treatment group were given atorvastatin 20rag, besides the conventional therapy. The levels of blood lipids,IL-6,hs-CRP were detected before and after the treatments. Results After treatment, the levels of blood lipids,IL-6 and hs-CRP in control treatment group and treatment group were significantly reduced, as compared with those before treatment （ P 〈0.01 ） ,furthermore the decrease in treatment group was more obvious than that in control treatment group （ P 〈 0.01 ）, however, the decrease of blood lipid levels before treatment in control treatment group and treatment group was not related with the decrease of levels of IL-6 and hs-CRP （ P 〉 0.05）. Conclusion The atorvastatin can reduce the levels of blood lipid, IL-6 and hs-CRP in patients with UAP, and the effect of atorvastatin 20mg is superior to that of atorvastatin 10mg, however, its anti-inflammatory effect is not independent of the effect of reducing blood lipid.